Buserelin as primary therapy in advanced prostatic carcinoma

Cary A. Presant; Mark S. Soloway; Sol S. Klioze; John W. Kosola; Alun L. Yakabow; Rafael G. Mendez; Peter S. Kennedy; Melody R. Wyres; Virginia L. Naessig; Kimball S. Ford; Charles L. Wiseman; Armand Bouzaglou; Barton Tanenbaum; Daniel Eventov

doi:10.1002/1097-0142(19851115)56:10<2416::AID-CNCR2820561013>3.0.CO;2-#

Buserelin as primary therapy in advanced prostatic carcinoma

Cary A. Presant, Mark S. Soloway, Sol S. Klioze, John W. Kosola, Alun L. Yakabow, Rafael G. Mendez, Peter S. Kennedy, Melody R. Wyres, Virginia L. Naessig, Kimball S. Ford, Charles L. Wiseman, Armand Bouzaglou, Barton Tanenbaum, Daniel Eventov

Urology

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

The effectiveness of buserelin, a luteinizing hormone-releasing hormone agonist, was tested in 28 patients with Stages C or D adenocarcinoma of the prostate. Of 24 evaluable patients, there were 13 partial responses (54%) by National Prostatic Cancer Project criteria, median duration greater than 6 months. Nine patients had stable disease (38%), median duration greater than 5 months, and only 2 patients progressed. Performance status improved in 38%, patient-scored pain improved in 46%, and quality of life improved in 57%. Symptoms occurring during treatment consisted of hot flashes, loss of libido, and impotence. A flare of symptoms was observed in only one patient, despite a transient 25% increase in testosterone in 36% of patients. Buserelin is an effective treatment for inducing frequent and meaningful remissions in advanced prostatic cancer.

Original language	English (US)
Pages (from-to)	2416-2419
Number of pages	4
Journal	Cancer
Volume	56
Issue number	10
DOIs	https://doi.org/10.1002/1097-0142(19851115)56:10<2416::AID-CNCR2820561013>3.0.CO;2-#
State	Published - Nov 15 1985

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following Sustainable Development Goal(s)

Access to Document

10.1002/1097-0142(19851115)56:10<2416::AID-CNCR2820561013>3.0.CO;2-#

Fingerprint Dive into the research topics of 'Buserelin as primary therapy in advanced prostatic carcinoma'. Together they form a unique fingerprint.

Cite this

Presant, C. A., Soloway, M. S., Klioze, S. S., Kosola, J. W., Yakabow, A. L., Mendez, R. G., Kennedy, P. S., Wyres, M. R., Naessig, V. L., Ford, K. S., Wiseman, C. L., Bouzaglou, A., Tanenbaum, B., & Eventov, D. (1985). Buserelin as primary therapy in advanced prostatic carcinoma. Cancer, 56(10), 2416-2419. https://doi.org/10.1002/1097-0142(19851115)56:10<2416::AID-CNCR2820561013>3.0.CO;2-#

Buserelin as primary therapy in advanced prostatic carcinoma. / Presant, Cary A.; Soloway, Mark S.; Klioze, Sol S.; Kosola, John W.; Yakabow, Alun L.; Mendez, Rafael G.; Kennedy, Peter S.; Wyres, Melody R.; Naessig, Virginia L.; Ford, Kimball S.; Wiseman, Charles L.; Bouzaglou, Armand; Tanenbaum, Barton; Eventov, Daniel.

In: Cancer, Vol. 56, No. 10, 15.11.1985, p. 2416-2419.

Research output: Contribution to journal › Article › peer-review

Presant, Cary A. ; Soloway, Mark S. ; Klioze, Sol S. ; Kosola, John W. ; Yakabow, Alun L. ; Mendez, Rafael G. ; Kennedy, Peter S. ; Wyres, Melody R. ; Naessig, Virginia L. ; Ford, Kimball S. ; Wiseman, Charles L. ; Bouzaglou, Armand ; Tanenbaum, Barton ; Eventov, Daniel. / Buserelin as primary therapy in advanced prostatic carcinoma. In: Cancer. 1985 ; Vol. 56, No. 10. pp. 2416-2419.

@article{deb53b965d7c4742b1647adde806b163,

title = "Buserelin as primary therapy in advanced prostatic carcinoma",

abstract = "The effectiveness of buserelin, a luteinizing hormone-releasing hormone agonist, was tested in 28 patients with Stages C or D adenocarcinoma of the prostate. Of 24 evaluable patients, there were 13 partial responses (54%) by National Prostatic Cancer Project criteria, median duration greater than 6 months. Nine patients had stable disease (38%), median duration greater than 5 months, and only 2 patients progressed. Performance status improved in 38%, patient-scored pain improved in 46%, and quality of life improved in 57%. Symptoms occurring during treatment consisted of hot flashes, loss of libido, and impotence. A flare of symptoms was observed in only one patient, despite a transient 25% increase in testosterone in 36% of patients. Buserelin is an effective treatment for inducing frequent and meaningful remissions in advanced prostatic cancer.",

author = "Presant, {Cary A.} and Soloway, {Mark S.} and Klioze, {Sol S.} and Kosola, {John W.} and Yakabow, {Alun L.} and Mendez, {Rafael G.} and Kennedy, {Peter S.} and Wyres, {Melody R.} and Naessig, {Virginia L.} and Ford, {Kimball S.} and Wiseman, {Charles L.} and Armand Bouzaglou and Barton Tanenbaum and Daniel Eventov",

year = "1985",

month = nov,

day = "15",

doi = "10.1002/1097-0142(19851115)56:10<2416::AID-CNCR2820561013>3.0.CO;2-#",

language = "English (US)",

volume = "56",

pages = "2416--2419",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "10",

}

TY - JOUR

T1 - Buserelin as primary therapy in advanced prostatic carcinoma

AU - Presant, Cary A.

AU - Soloway, Mark S.

AU - Klioze, Sol S.

AU - Kosola, John W.

AU - Yakabow, Alun L.

AU - Mendez, Rafael G.

AU - Kennedy, Peter S.

AU - Wyres, Melody R.

AU - Naessig, Virginia L.

AU - Ford, Kimball S.

AU - Wiseman, Charles L.

AU - Bouzaglou, Armand

AU - Tanenbaum, Barton

AU - Eventov, Daniel

PY - 1985/11/15

Y1 - 1985/11/15

N2 - The effectiveness of buserelin, a luteinizing hormone-releasing hormone agonist, was tested in 28 patients with Stages C or D adenocarcinoma of the prostate. Of 24 evaluable patients, there were 13 partial responses (54%) by National Prostatic Cancer Project criteria, median duration greater than 6 months. Nine patients had stable disease (38%), median duration greater than 5 months, and only 2 patients progressed. Performance status improved in 38%, patient-scored pain improved in 46%, and quality of life improved in 57%. Symptoms occurring during treatment consisted of hot flashes, loss of libido, and impotence. A flare of symptoms was observed in only one patient, despite a transient 25% increase in testosterone in 36% of patients. Buserelin is an effective treatment for inducing frequent and meaningful remissions in advanced prostatic cancer.

AB - The effectiveness of buserelin, a luteinizing hormone-releasing hormone agonist, was tested in 28 patients with Stages C or D adenocarcinoma of the prostate. Of 24 evaluable patients, there were 13 partial responses (54%) by National Prostatic Cancer Project criteria, median duration greater than 6 months. Nine patients had stable disease (38%), median duration greater than 5 months, and only 2 patients progressed. Performance status improved in 38%, patient-scored pain improved in 46%, and quality of life improved in 57%. Symptoms occurring during treatment consisted of hot flashes, loss of libido, and impotence. A flare of symptoms was observed in only one patient, despite a transient 25% increase in testosterone in 36% of patients. Buserelin is an effective treatment for inducing frequent and meaningful remissions in advanced prostatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=0022406964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022406964&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19851115)56:10<2416::AID-CNCR2820561013>3.0.CO;2-#

DO - 10.1002/1097-0142(19851115)56:10<2416::AID-CNCR2820561013>3.0.CO;2-#

M3 - Article

C2 - 3930064

AN - SCOPUS:0022406964

VL - 56

SP - 2416

EP - 2419

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 10

ER -

Buserelin as primary therapy in advanced prostatic carcinoma

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this